<DOC>
	<DOCNO>NCT01674621</DOCNO>
	<brief_summary>To determine clinical safety efficacy BA058 Transdermal otherwise healthy postmenopausal woman osteoporosis assess change bone mineral density ( BMD ) serum marker bone metabolism compare Transdermal Placebo BA058 Injection 6 month treatment .</brief_summary>
	<brief_title>Phase 2 Study BA058 ( Abaloparatide ) Transdermal Delivery Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Postmenopausal woman , less 85 year old . BMD Tscore ≤ 2.5 spine hip ( femoral neck ) ≤ 2.0 previous fracture ( within 5 year ) . Normal physical exam , vital sign , electrocardiogram ( ECG ) medical history . Laboratory test within normal range include serum calcium , Vit D , PTH ( 184 ) , serum phosphorus alkaline phosphatase . BMD Tscore ≤ 5.0 lumbar spine hip . History bone disorder ( e.g. , Paget 's disease ) postmenopausal osteoporosis . Significantly impaired renal function . History cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>BA058</keyword>
	<keyword>Abaloparatide-SC</keyword>
	<keyword>abaloparatide</keyword>
	<keyword>Abaloparatide-TD</keyword>
	<keyword>Osteo</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Transdermal</keyword>
	<keyword>Patch</keyword>
</DOC>